Further assessment of rosette inhibition test in clinical organ transplantation.
The rosette inhibition test was used in the clinical management of organ allografts to estimate the amount of immunosuppressive drugs necessary to prevent rejection. In patients surviving more than three months renal function appeared to be better than in a similar group of patients managed without the test. It is suggested that this was due to a reduction in the number of clinical or subclinical rejection episodes. On the other hand, the test indicates that in many cases the level of immunosuppression should be much higher, and if this advice is followed the patients become increasingly exposed to the risk of infection. In other words, those patients with good renal function remained well, whereas those who might otherwise have rejected their kidney and survived had in fact died of sepsis.
D000818:Animals; D000917:Antibody Formation; D000937:Antigen-Antibody Reactions; D000961:Antilymphocyte Serum / Q000008:administration & dosage; D001379:Azathioprine / Q000008:administration & dosage; D002102:Cadaver; D004912:Erythrocytes; D006084:Graft Rejection / Q000187:drug effects / Q000528:radiation effects; D006801:Humans; D007104:Immune Adherence Reaction; D007165:Immunosuppression Therapy; D007668:Kidney / Q000502:physiology; D016030:Kidney Transplantation; D008214:Lymphocytes / Q000276:immunology; D011241:Prednisone / Q000008:administration & dosage; D011878:Radiotherapy; D012756:Sheep / Q000276:immunology; D013530:Surgical Wound Infection / Q000209:etiology; D014184:Transplantation, Homologous
D000961:Antilymphocyte Serum; D001379:Azathioprine; D011241:Prednisone